A Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 1 Study to Determine the Safety, Tolerability, Pharmacokinetics and Effect of Circulating Alpha-1 Antitrypsin Levels of ARC-AAT in Healthy Volunteer Subjects and in Patients With Alpha-1 Antitrypsin Deficiency (AATD)

Trial Profile

A Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 1 Study to Determine the Safety, Tolerability, Pharmacokinetics and Effect of Circulating Alpha-1 Antitrypsin Levels of ARC-AAT in Healthy Volunteer Subjects and in Patients With Alpha-1 Antitrypsin Deficiency (AATD)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs ARC AAT (Primary)
  • Indications Alpha 1-antitrypsin deficiency; Liver disorders
  • Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
  • Sponsors Arrowhead Pharmaceuticals
  • Most Recent Events

    • 24 Apr 2017 According to an Arrowhead Pharmaceuticals media release, data from this trial presented at The International Liver Congress 2017 (ILC), the annual meeting of the European Association for the Study of the Liver (EASL).
    • 04 Jan 2017 Planned End Date changed from 1 Mar 2017 to 1 Feb 2017.
    • 04 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Feb 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top